Drugs / DE-111
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01342081 | May 2011 → Sep 2012 | ocular hypertension, open-angle glaucoma | Santen Pharmaceutical Co., Ltd. | Completed | Met primary |
| Phase 3 | NCT01343082 | May 2011 → Mar 2013 | open-angle glaucoma | Santen Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT01342094 | May 2011 → Sep 2012 | ocular hypertension, open-angle glaucoma | Santen Pharmaceutical Co., Ltd. | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DE-111 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01343082 ↗ |
| Route | Other | “DE-111 ophthalmic solution (one drop at a time, once daily)” NCT01342094 ↗ |